Related Experiment Video
Updated: Aug 19, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns
1Department of Neurology, St Vincent's University Hospital, Dublin, Ireland.
Unlabelled:
Estimates of the beta-interferon (IFNB) stopping rate in relapsing-remitting multiple sclerosis (RRMS) and secondary progressive MS (SPMS) vary and have been mainly derived from multicentre studies. This is a retrospective, hospital chart-based study of 394 patients treated by a single neurologist for up to eight years. The aims of the study were to ascertain the frequency and timing of IFNB discontinuation in a well supported cohort, and to investigate whether the clinical disease type at the initiation of IFNB or the reason for discontinuation influenced stopping rates. The median follow-up was 49 months. The overall IFNB stopping rate was 28% over five years; there was a significant difference between the IFNB stopping rates for RRMS (14%) and SPMS (23%) after three years of follow-up (P =0.0003). Patients stopped IFNB due to side effects after a median of 13 months, and due to failure of therapy after a median of 35 months (P =0.0004). Significantly more patients with SPMS than with RRMS stopped IFNB due to treatment failure (P =0.037).
Conclusion:
IFNB discontinuation occurred earlier in the treatment course when due to side effects. Stopping IFNB therapy was more common in SPMS and was more often due to treatment failure than side effects.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Therapeutic Drug Monitoring: Affecting Factors
Multiple Sclerosis l: Introduction
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Therapeutic Drug Monitoring: Drug Analysis Methods
